vismodegib和sonidegib治疗晚期基底细胞癌的实际经验：一项意大利多中心研究。

IF 1.3 Q2 DERMATOLOGY

Dermatology Reports Pub Date : 2025-08-22 Epub Date: 2025-02-18 DOI:10.4081/dr.2025.10196

Mario Valenti, Sara Di Giulio, Andrea Carugno, Pasquale Frascione, Angelo Valerio Marzano, Santo Raffaele Mercuri, Gianluca Nazzaro, Giulia Spallone, Giovanni Paolino, Marco Ardigò

{"title":"vismodegib和sonidegib治疗晚期基底细胞癌的实际经验：一项意大利多中心研究。","authors":"Mario Valenti, Sara Di Giulio, Andrea Carugno, Pasquale Frascione, Angelo Valerio Marzano, Santo Raffaele Mercuri, Gianluca Nazzaro, Giulia Spallone, Giovanni Paolino, Marco Ardigò","doi":"10.4081/dr.2025.10196","DOIUrl":null,"url":null,"abstract":"Vismodegib and sonidegib are smoothened (SMO) inhibitors approved for the treatment of advanced basal cell carcinoma (aBCC). This study investigates the real-world experiences and outcomes associated with these therapies across multiple Italian centers. A retrospective, observational, multicenter study was conducted. Medical records of patients with local advanced basal cell carcinoma (laBCC) treated with SMO inhibitors outside of clinical trials from July 2019 to April 2024 were analyzed. A total of 57 patients were included in the study, with 19 (33.3%) receiving vismodegib and 38 (66.7%) receiving sonidegib. Vismodegib demonstrated a complete response (CR) in 31.6% of cases and a partial response (PR) in 26.3%. Sonidegib achieved a CR of 47.4% and a PR of 36.8%. The median treatment duration was 8 months for vismodegib and 12 months for sonidegib. Adverse events were more frequently reported with vismodegib. Treatment interruption due to adverse events occurred in 47.4% of vismodegib recipients and in 13.2% of those receiving sonidegib. The progression of the disease under treatment occurred in 7.9% of cases of patients under sonidegib and in 26.3% of cases under vismodegib. ************************************************************************* *Appendix Authors list Valentina Benzecry Mancin,1 Veronica Benzi,2 Matteo Bianco,2,3 Alessandra Bulotta,4 Antonio Costanzo,2,3 Giuseppe Damiano,5 Nerina Denaro,6 Laura Eibenschutz,7 Barbara Merelli,8 Giulia Murgia,1 Alessandra Narcisi,3 Emanuela Passoni,1 Francesco Piscazzi,2,3 Vincenzo Russo5 1Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan; 2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI); 3Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI); 4Department of Oncology, IRCCS San Raffaele, Milan; 5Unit of Immuno-Biotherapy of Melanoma and Solid Tumors, IRCCS Ospedale San Raffaele, Milan; 6Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan; 7Oncologic and Preventive Dermatology Unit, IFO-San Gallicano Dermatological Institute IRCCS, Rome; 8Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481491/pdf/","citationCount":"0","resultStr":"{\"title\":\"Real-world experience with vismodegib and sonidegib in advanced basal cell carcinoma: a multicenter Italian study.\",\"authors\":\"Mario Valenti, Sara Di Giulio, Andrea Carugno, Pasquale Frascione, Angelo Valerio Marzano, Santo Raffaele Mercuri, Gianluca Nazzaro, Giulia Spallone, Giovanni Paolino, Marco Ardigò\",\"doi\":\"10.4081/dr.2025.10196\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Vismodegib and sonidegib are smoothened (SMO) inhibitors approved for the treatment of advanced basal cell carcinoma (aBCC). This study investigates the real-world experiences and outcomes associated with these therapies across multiple Italian centers. A retrospective, observational, multicenter study was conducted. Medical records of patients with local advanced basal cell carcinoma (laBCC) treated with SMO inhibitors outside of clinical trials from July 2019 to April 2024 were analyzed. A total of 57 patients were included in the study, with 19 (33.3%) receiving vismodegib and 38 (66.7%) receiving sonidegib. Vismodegib demonstrated a complete response (CR) in 31.6% of cases and a partial response (PR) in 26.3%. Sonidegib achieved a CR of 47.4% and a PR of 36.8%. The median treatment duration was 8 months for vismodegib and 12 months for sonidegib. Adverse events were more frequently reported with vismodegib. Treatment interruption due to adverse events occurred in 47.4% of vismodegib recipients and in 13.2% of those receiving sonidegib. The progression of the disease under treatment occurred in 7.9% of cases of patients under sonidegib and in 26.3% of cases under vismodegib. ************************************************************************* *Appendix Authors list Valentina Benzecry Mancin,1 Veronica Benzi,2 Matteo Bianco,2,3 Alessandra Bulotta,4 Antonio Costanzo,2,3 Giuseppe Damiano,5 Nerina Denaro,6 Laura Eibenschutz,7 Barbara Merelli,8 Giulia Murgia,1 Alessandra Narcisi,3 Emanuela Passoni,1 Francesco Piscazzi,2,3 Vincenzo Russo5 1Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan; 2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI); 3Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI); 4Department of Oncology, IRCCS San Raffaele, Milan; 5Unit of Immuno-Biotherapy of Melanoma and Solid Tumors, IRCCS Ospedale San Raffaele, Milan; 6Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan; 7Oncologic and Preventive Dermatology Unit, IFO-San Gallicano Dermatological Institute IRCCS, Rome; 8Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.\",\"PeriodicalId\":11049,\"journal\":{\"name\":\"Dermatology Reports\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-08-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481491/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/dr.2025.10196\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/dr.2025.10196","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Vismodegib和sonidegib是被批准用于治疗晚期基底细胞癌（aBCC）的平滑（SMO）抑制剂。本研究调查了意大利多个中心与这些疗法相关的现实经验和结果。本研究采用回顾性、观察性、多中心研究。分析2019年7月至2024年4月局部晚期基底细胞癌（laBCC）患者在临床试验外接受SMO抑制剂治疗的病历。研究共纳入57例患者，其中19例（33.3%）接受vismodegib治疗，38例（66.7%）接受sonidegib治疗。Vismodegib在31.6%的病例中显示完全缓解（CR），在26.3%的病例中显示部分缓解（PR）。Sonidegib的CR为47.4%，PR为36.8%。vismodegib的中位治疗时间为8个月，sonidegib的中位治疗时间为12个月。使用维莫德吉的不良事件报告更为频繁。因不良事件而中断治疗的发生率为47.4%的维莫地吉接受者和13.2%的索尼地吉接受者。在接受sonidegib治疗的患者中，7.9%的患者在治疗过程中出现疾病进展，而在接受vismodegib治疗的患者中，这一比例为26.3%。*************************************************************** *附录作者名单：Valentina Benzecry Mancin，1 Veronica Benzi,2 Matteo Bianco,2,3 Alessandra Bulotta,4 Antonio Costanzo,2,3 Giuseppe Damiano,5 Nerina Denaro,6 Laura Eibenschutz,7 Barbara Merelli,8 Giulia Murgia,1 Alessandra Narcisi,3 Emanuela Passoni,1 Francesco Piscazzi,2,3 Vincenzo Russo5 1米兰grande Ospedale Maggiore Policlinico基金会皮肤病科；2人文大学生物医学科学系，米兰Pieve Emanuele；3米兰罗萨诺IRCCS人道主义研究医院皮肤病科；4米兰圣拉斐尔IRCCS肿瘤科；5米兰Ospedale San Raffaele IRCCS黑色素瘤和实体瘤免疫生物疗法单位；6米兰Maggiore polilinico grande Ospedale基金会肿瘤科；7罗马国际癌症研究所圣加利卡诺皮肤病研究所肿瘤学和预防皮肤科；8肿瘤科，意大利贝加莫Papa Giovanni XXIII助理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Real-world experience with vismodegib and sonidegib in advanced basal cell carcinoma: a multicenter Italian study.

查看原文本刊更多论文

Real-world experience with vismodegib and sonidegib in advanced basal cell carcinoma: a multicenter Italian study.

Vismodegib and sonidegib are smoothened (SMO) inhibitors approved for the treatment of advanced basal cell carcinoma (aBCC). This study investigates the real-world experiences and outcomes associated with these therapies across multiple Italian centers. A retrospective, observational, multicenter study was conducted. Medical records of patients with local advanced basal cell carcinoma (laBCC) treated with SMO inhibitors outside of clinical trials from July 2019 to April 2024 were analyzed. A total of 57 patients were included in the study, with 19 (33.3%) receiving vismodegib and 38 (66.7%) receiving sonidegib. Vismodegib demonstrated a complete response (CR) in 31.6% of cases and a partial response (PR) in 26.3%. Sonidegib achieved a CR of 47.4% and a PR of 36.8%. The median treatment duration was 8 months for vismodegib and 12 months for sonidegib. Adverse events were more frequently reported with vismodegib. Treatment interruption due to adverse events occurred in 47.4% of vismodegib recipients and in 13.2% of those receiving sonidegib. The progression of the disease under treatment occurred in 7.9% of cases of patients under sonidegib and in 26.3% of cases under vismodegib. ************************************************************************* *Appendix Authors list Valentina Benzecry Mancin,1 Veronica Benzi,2 Matteo Bianco,2,3 Alessandra Bulotta,4 Antonio Costanzo,2,3 Giuseppe Damiano,5 Nerina Denaro,6 Laura Eibenschutz,7 Barbara Merelli,8 Giulia Murgia,1 Alessandra Narcisi,3 Emanuela Passoni,1 Francesco Piscazzi,2,3 Vincenzo Russo5 1Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan; 2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI); 3Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI); 4Department of Oncology, IRCCS San Raffaele, Milan; 5Unit of Immuno-Biotherapy of Melanoma and Solid Tumors, IRCCS Ospedale San Raffaele, Milan; 6Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan; 7Oncologic and Preventive Dermatology Unit, IFO-San Gallicano Dermatological Institute IRCCS, Rome; 8Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Dermatology Reports DERMATOLOGY-

CiteScore

1.40

自引率

0.00%

发文量

审稿时长

10 weeks